Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer
Year: 2019
Type: article
Study design: Clinical Trial
Source: Pancreatology
Authors: Angela L. McCleary-Wheeler, Ryan M. Carr, Shanique R. Palmer, Thomas C. Smyrk, Jacob B. Allred, Luciana L. Almada, Ezequiel J. Tolosa, Maria J. Lamberti, David L. Marks, Mitesh J. Borad, Julian R. Molina, Yingwei Qi, Wilma L. Lingle, Axel Grothey, Henry C. Pitot, Aminah Jatoi, Donald W. Northfelt, Alan H. Bryce, Robert R. McWilliams, Scott H. Okuno, Paul Haluska, George P. Kim, Gerardo Colon-Otero, Val J. Lowe, Matthew R. Callstrom, Wen We Ma, Tanios Bekaii-Saab, Mien-Chie Hung, Charles Erlichman, Martin E. Fernandez-Zapico
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Mayo Clinic, National Cancer Institute
Awards: G1828094709, Mayo Clinic SPORE in Pancreatic Cancer, NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis, Mayo Clinic SPORE in Pancreatic Cancer, G703126342, Mechanism of Pancreatic Carcinogenesis, G8360688006, G8527824803, Mayo Clinic Comprehensive Cancer Center Support Grant
OpenAlex ID: W2989592254